Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So
HC Wainwright has removed Angion Biomedica Corp's (NASDAQ:ANGN) former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation assessment. The analyst has reduced the price target from $50 to $32, with a Buy rating. In the Q4 earnings release, the Company decided to discontinue the development of ANG-3777 after disappointing data. The analyst…
Benzinga ·
Benzinga
